As the market for GLP-1 agonists expands, biotech companies face both immense opportunity and fierce competition. To stand out in this evolving landscape and enhance the likelihood of acquisition or out-licensing, early-stage companies must develop a strategic, data-driven clinical development plan.

Quantitative systems pharmacology (QSP) modeling offers a powerful approach to optimize the clinical strategy for GLP-1 drug candidates, integrating complex biological and pharmacological data to predict efficacy, safety, and patient response.

In this webinar, Dr. Scott Q. Siler, Chief Science Officer of Quantitative Systems Pharmacology at Simulations Plus, will demonstrate how biotech innovators can leverage QSP modeling to:

• Inform optimal dosing paradigms and trial design to accelerate development timelines
• Simultaneously predict efficacy and adverse events to strengthen regulatory and investor confidence – De-risk potential liabilities before costly clinical setbacks
• Identify combination treatment approaches that can be carried into clinical trials
• Generate compelling data packages that enhance the commercial appeal of their asset

The session will conclude with a live Q&A, allowing attendees to engage directly with Dr. Siler and gain expert insights on applying QSP to maximize the value of their GLP-1 drug candidates.